ICU Medical (NASDAQ: ICUI) reported Q4 EPS of $0.68, $0.09 better than the analyst estimate of $0.59. Revenue for the quarter came in at $79.9 million versus the consensus estimate of $76.01 million.

Vivek Jain, ICU Medical's Chief Executive Officer, said, "Fourth quarter and full year results were slightly above our expectations. Consistent with our trends during the previous two quarters, fourth quarter revenue was driven by strength in direct infusion therapy, oncology and international sales and this was offset by an expected decline in our OEM business."

For earnings history and earnings-related data on ICU Medical (ICUI) click here.